PRF: Consolidated Unaudited Interim Report of AS PRFoods for 4th quarter and 12 months of 2015
OREANDA-NEWS.
Overview of the Economic Activities
MANAGEMENT COMMENTARY
PRFoods management is very pleased with the results of 2015, we exceeded the budget both on sales and profitability despite challenging macro environment in our key markets of Finland and Estonia. Volatility in raw fish prices was counterbalanced by impressive production efficiency and sales efforts by our team. The company implemented its investment program on time and on budget. 2015 was first full year for the company as dedicated value added fish processing company and the results prove that company is on right track. PRFoods will maintain its target to be one of the most profitable companies in the sector and favourite for the customers. PRFoods will announce the dividend amount once the audit for 2015 is completed.
UNAUDITED FINANCIAL RESULTS OF AS PRFOODS, THE 4TH QUARTER OF 2015 COMPARED TO THE 4THQUARTER OF 2014
- Unaudited consolidated revenue 17.2 million euros, increase 19.7%, i.e. 2.8 million euros.
- Gross margin 14.9%, increase 3.1 percentage points.
- The negative effect of revaluation of biological assets 0.4 million euros (Q4 2014: 0.3 million euros).
- EBITDA from business operations 1.4 million euros, increase 1.7 million euros.
- EBITDA 1.0 million euros, increase 1.7 million euros.
- EBIT 0.7 million euros, increase 1.6 million euros.
- Net profit 0.7 million euros, increase 2.0 million euros.
UNAUDITED FINANCIAL RESULTS OF AS PRFOODS, 12 MONTHS OF 2015 COMPARED TO 12 MONTHS OF 2014
- Unaudited consolidated revenue 50.3 million euros, increase 9.6%, i.e. 4.4 million euros.
- Gross margin 13.4%, increase 1.9 percentage points.
- The negative effect of revaluation of biological assets 0.9 million euros (12 months 2014: 0.6 million euros).
- EBITDA from business operations 2.9 million euros, increase 2.5 million euros.
- EBITDA 2.0 million euros, increase 1.5 million euros*.
- EBIT 0.9 million euros, increase 1.5 million euros.
- Net profit 1.2 million euros, increase 2.7 million euros.
* Negative effect in comparing data of EBITDA, EBIT and net profit is caused by the reimbursement of a claim in the amount of 751 thousand euros received in June 2014 from the Swedish Board of Agriculture, recorded in the income statement of Q2 2014 on line “Other business incomes/costs”.
KEY RATIOS
Profit & Loss, EUR mln | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | 12m 15 | Q1 2014 | Q2 2014 | Q3 2014 | Q4 2014 | 12m 14 |
Sales | 10.3 | 11.4 | 11.4 | 17.2 | 50.3 | 10.2 | 11.3 | 10.0 | 14.3 | 45.9 |
Gross profit | 1.3 | 1.3 | 1.6 | 2.6 | 6.8 | 1.4 | 1.0 | 1.2 | 1.7 | 5.3 |
EBITDA from operations | 0.4 | 0.4 | 0.7 | 1.4 | 2.9 | 0.5 | -0.1 | 0.3 | -0.3 | 0.4 |
EBITDA | -0.6 | 0.6 | 1.1 | 1.0 | 2.0 | -0.7 | 1.1 | 0.7 | -0.7 | 0.5 |
EBIT | -0.9 | 0.3 | 0.8 | 0.7 | 0.9 | -0.9 | 0.8 | 0.4 | -0.9 | -0.6 |
EBT | -0.8 | 0.3 | 0.8 | 0.7 | 1.1 | -1.2 | 0.8 | 0.2 | -1.2 | -1.4 |
Net profit (-loss) | -0.5 | 0.3 | 0.7 | 0.7 | 1.2 | -0.9 | 0.6 | 0.1 | -1.3 | -1.5 |
Gross margin | 12.2% | 11.3% | 14.5% | 14.9% | 13.4% | 13.8% | 8.6% | 12.2% | 11.8% | 11.5% |
Operational EBITDA margin | 4.1% | 3.3% | 6.5% | 7.9% | 5.8% | 4.9% | -1.1% | 3.4% | -2.4% | 0.8% |
EBITDA margin | -5.9% | 4.8% | 9.4% | 5.9% | 4.0% | -6.5% | 10.0% | 7.1% | -4.6% | 1.1% |
EBIT margin | -8.6% | 2.4% | 6.8% | 4.1% | 1.7% | -9.2% | 7.5% | 4.3% | -6.6% | -1.3% |
EBT margin | -7.4% | 2.9% | 6.6% | 4.3% | 2.1% | -11.7% | 7.0% | 2.0% | -8.2% | -3.0% |
Net margin | -5.2% | 2.5% | 6.1% | 4.2% | 2.3% | -9.2% | 5.2% | 1.2% | -8.9% | -3.3% |
Operating expense ratio | 11.3% | 11.3% | 11.9% | 9.3% | 10.8% | 12.6% | 12.7% | 13.2% | 14.7% | 13.4% |
Balance Sheet, EUR mln | 31/03/2015 | 30/06/2015 | 30/09/2015 | 31/12/2015 | 31/03/2014 | 30/06/2014 | 30/09/2014 | 31/12/2014 |
Net debt | -3.3 | -6.5 | -5.2 | -0.6 | 13.6 | 13.7 | 9.7 | -2.6 |
Equity | 33.1 | 33.3 | 34.0 | 23.2 | 36.1 | 37.9 | 40.5 | 33.7 |
Working capital | 21.8 | 21.8 | 22.0 | 11.5 | 8.5 | 9.9 | 8.1 | 22.8 |
Assets | 39.5 | 39.4 | 40.1 | 29.5 | 63.8 | 68.5 | 65.6 | 40.4 |
Liquidity ratio | 5.7 | 6.2 | 6.2 | 3.8 | 1.5 | 1.5 | 2.1 | 5.9 |
Equity ratio | 83.9% | 84.6% | 84.7% | 78.7% | 56.5% | 55.3% | 61.6% | 83.3% |
Gearing ratio | -11.0% | -24.1% | -18.2% | -2.5% | 27.4% | 26.6% | 19.3% | -8.3% |
Net debt-to-EBITDA | -11.2 | -8.2 | -4.4 | -0.2 | 15.6 | 16.1 | 7.1 | -7.0 |
ROE | -3.2% | -3.9% | -2.3% | 4.1% | -3.6% | 0.8% | 0.3% | -4.2% |
ROA | -2.1% | -2.6% | -1.6% | 3.4% | -2.0% | 0.4% | 0.2% | -2.9% |
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
EUR '000 | 31/12/2015 | 31/12/2014 |
ASSETS | ||
Cash and cash equivalents | 1,921 | 3,330 |
Receivables and prepayments | 3,691 | 12,014 |
Inventories | 5,616 | 6,563 |
Biological assets | 4,422 | 5,583 |
Total current assets | 15,650 | 27,490 |
Deferred income tax | 137 | 103 |
Long-term financial investments | 161 | 134 |
Tangible fixed assets | 7,427 | 6,484 |
Intangible assets | 6,128 | 6,218 |
Total non-current assets | 13,853 | 12,939 |
TOTAL ASSETS | 29,503 | 40,429 |
EQUITY AND LIABILITIES | ||
Loans and borrowings | 286 | 198 |
Payables | 3,817 | 4,493 |
Total current liabilities | 4,103 | 4,691 |
Loans and borrowings | 1,061 | 555 |
Deferred tax liabilities | 244 | 457 |
Government grants | 883 | 1,054 |
Total non-current liabilities | 2,188 | 2,066 |
TOTAL LIABILITIES | 6,291 | 6,757 |
Share capital | 7,737 | 19,342 |
Share premium | 16,026 | 16,026 |
Treasury shares | -172 | -117 |
Statutory capital reserve | 6 | 6 |
Currency translation reserve | 469 | 441 |
Retained profit (-loss) | -854 | -2,026 |
TOTAL EQUITY | 23,212 | 33,672 |
TOTAL EQUITY AND LIABILITIES | 29,503 | 40,429 |
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
EUR '000 | Q4 2015 | Q4 2014 | 12m 2015 | 12m 2014 |
Sales | 17,178 | 14,348 | 50,273 | 45,863 |
Cost of goods sold | -14,611 | -12,661 | -43,521 | -40,581 |
Gross profit | 2,567 | 1,687 | 6,752 | 5,282 |
Operating expenses | -1,606 | -2,107 | -5,418 | -6,153 |
Selling and distribution expenses | -1,228 | -912 | -4,012 | -3,598 |
Administrative expenses | -378 | -1,195 | -1,406 | -2,555 |
Other income/expenses | 96 | -201 | 406 | 831 |
Fair value adjustment on biological assets | -359 | -323 | -888 | -571 |
Operating profit (-loss) | 698 | -944 | 852 | -611 |
Financial income | 65 | 75 | 303 | 87 |
Financial expenses | -23 | -305 | -103 | -844 |
Profit (-loss) before tax | 740 | -1,174 | 1,052 | -1,368 |
Income tax | -10 | -106 | 120 | -136 |
Net profit (-loss) for the year from continuing operations | 730 | -1,280 | 1,172 | -1,504 |
Net loss for the year from discontinuing operations (attributable to equity holders of the company) | 0 | -5,206 | 0 | -1,310 |
Net profit (loss) | 730 | -6,486 | 1,172 | -2,814 |
Other comprehensive income (-expense) that might subsequently classified to profit or loss: | ||||
Foreign currency translation differences | 30 | -256 | 28 | -308 |
including continued operations | 30 | -33 | 28 | -98 |
including discontinued operations | 0 | -223 | 0 | -210 |
Total comprehensive income (-expense) | 760 | -6,742 | 1,200 | -3,122 |
Profit (-loss) per share (€) | 0.02 | -0.17 | 0.03 | -0.07 |
including continued operations | 0.02 | -0.03 | 0.03 | -0.04 |
including discontinued operations | 0.00 | -0.13 | 0.00 | -0.03 |
Diluted profit (-loss) per share (€) | 0.02 | -0.17 | 0.03 | -0.07 |
including continued operations | 0.02 | -0.03 | 0.03 | -0.04 |
including discontinued operations | 0.00 | -0.13 | 0.00 | -0.03 |
Комментарии